April 30th 2025
The company’s intent is to establish Merck Wilmington Biotech as the future United States home for producing Keytruda for US patients.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
FDA Publishes Guidance on Therapeutic Protein Biosimilars
May 22nd 2019The guidance discusses the design and evaluation of comparative analytical studies used to support the biosimilarity of a proposed therapeutic protein product to a reference product licensed under section 351(a) of the Public Health Service Act.
Dyadic, Serum Institute of India Collaborate on Affordable and Accessible Antibodies
May 10th 2019Dyadic International has announced its collaboration agreement with Serum Institute of India for the development and manufacture of up to 12 antibodies and vaccines using Dyadic’s C1 gene expression system.